Beijing: AstraZeneca plc’s antibody cocktail for the prevention of Kovid-19 has been given a . has been approved for use in medical The tourism sector in China’s southern province of Hainan comes ahead of national approval, local media said on Tuesday.
China allows the early use of new medical products in the particular region, as part of a number of preferential policies given to the region to promote medical services to visitors both at home and abroad.
Hainan Daily, backed by the provincial Communist Party authority, reported that shipments of 21.98 million yuan ($3.28 million) of AstraZeneca’s antibody-based therapy Evusheld had completed procedures at local customs as a special import.
The drug has been authorized in many areas In the United States, the United Kingdom, and the European Union, to prevent infection in people whose immune system too weak to answer Vaccines,
AstraZeneca did not immediately respond to a Reuters request for comment.
Other Western products not yet approved for national use but are currently available in Hainan’s Boao Lecheng International Medical Tourism Pilot Zone include Novartis’s breast cancer drug Picare and Gilead’s fungal infection drug Ambisome. .
Merck’s blockbuster cancer treatment Keytruda was also approved for import into the region in 2016, before being approved nationally two years later.
FacebookTwitterinstagramKu APPyoutube